New hope for psoriasis: oral drug shows promise in chinese trial
NCT ID NCT06122649
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug apremilast (Otezla) in 203 Chinese adults with moderate to severe plaque psoriasis. Participants took either apremilast or a placebo pill twice daily for 16 weeks. The main goal was to see if more people on apremilast achieved at least a 75% improvement in their psoriasis skin symptoms compared to placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
apremilast (Otezla)
What this could lead to
If successful, this could provide a new oral treatment option for Chinese patients with moderate to severe plaque psoriasis, helping clear skin and reduce itching.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to all populations. Apremilast can cause side effects like nausea, diarrhea, and headache. It controls symptoms but does not cure psoriasis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Changshu No2 Peoples Hospital
Suzhou, Jiangsu, 215006, China
-
Chengdu Second Peoples Hospital
Chengdu, Sichuan, 610017, China
-
Dermatology Hospital of Jiangxi Province
Nanchang, Jiangxi, 330000, China
-
Dermatology Hospital of Southern Medical University
Guangzhou, Guangdong, 510091, China
-
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, 750003, China
-
Nanyang First Peoples Hospital
Nanyang, Henan, 473002, China
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100191, China
-
Peoples Hospital of Xinjiang Uygur Autonomous Region
Ürümqi, Xinjiang, 830001, China
-
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
-
Shandong Provincial Hospital For Skin Diseases,Shandong First Medical University
Jinan, Shandong, 830001, China
-
Shanghai Skin Disease Hospital
Shanghai, Shanghai Municipality, 200443, China
-
Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310016, China
-
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, 350000, China
-
The First Bethune Hospital of Jilin University
Changchun, Jilin, 130021, China
-
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Sichuan, 400010, China
-
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050000, China
-
The Second Xiangya Hospital of Central South University
Changsha, Hunan, 410011, China
-
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, 300052, China
-
Wuxi Peoples Hospital
Wuxi, Jiangsu, 241023, China
-
Yichang Central Peoples Hospital
Yichang, Hubei, 443003, China